Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan.

Trial Profile

Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary) ; Olmesartan medoxomil/amlodipine (Primary) ; Hydrochlorothiazide; Spironolactone
  • Indications Hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms AMORE
  • Most Recent Events

    • 19 May 2012 Results presented at the 27th Annual Scientific Meeting of the American Society of Hypertension.
    • 04 May 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 04 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top